The MarketWatch News Department was not involved in the creation of this content. SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Neomorph, Inc., a biotechnology company pioneering molecular glue ...
Orphan designation reflects unmet need in RP rather than evidence of efficacy, while offering development incentives and ...
91.5% of patients experienced a reduction in tumors and a disease control rate of 96.7%; nearly half the patients evaluated remain on treatment Low discontinuation rate due to adverse events of 4% ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The allogenic cell therapy achieved all primary and ...
MOONRAY-01, a phase 1 study of LY3962673, a potent, orally bioavailable, and selective KRAS G12D inhibitor in KRAS G12D-mutant solid tumors. This is an ASCO Meeting Abstract from the 2025 ASCO ...
AMSTERDAM & BOSTON--(BUSINESS WIRE)--VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) ...
STARLITE 2: Phase 2 study of nivolumab plus 177lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (177Lu-girentuximab) in patients with advanced clear cell renal cell ...
Nuvalent has reported phase 1/2 lung cancer data, teeing the biotech up to talk to the FDA about an approval filing that could establish its neladalkib as a challenger to Pfizer’s Lorbrena. The ALKOVE ...
The ongoing GARDian3 study is designed to assess whether a single subretinal administration of OCU410ST can slow structural ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results